Your browser doesn't support javascript.
loading
A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma.
Ghobrial, Irene M; Liu, Chia-Jen; Redd, Robert A; Perez, Raymond P; Baz, Rachid; Zavidij, Oksana; Sklavenitis-Pistofidis, Romanos; Richardson, Paul G; Anderson, Kenneth C; Laubach, Jacob; Henrick, Patrick; Savell, Alexandra; Reyes, Kaitlen; Hornburg, Kalvis; Chuma, Stacey; Sabbatini, Peter; Robbins, Michael D; Becker, Pamela S.
Afiliação
  • Ghobrial IM; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. irene_ghobrial@dfci.harvard.edu.
  • Liu CJ; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Redd RA; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Perez RP; University of Kansas, Fairway, Kansas.
  • Baz R; Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Zavidij O; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Sklavenitis-Pistofidis R; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Richardson PG; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Anderson KC; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Laubach J; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Henrick P; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Savell A; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Reyes K; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Hornburg K; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Chuma S; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Sabbatini P; Bristol-Myers Squibb, Sunnyvale, California.
  • Robbins MD; Bristol-Myers Squibb, Princeton, New Jersey.
  • Becker PS; Bristol-Myers Squibb, Sunnyvale, California.
Clin Cancer Res ; 26(2): 344-353, 2020 01 15.
Article em En | MEDLINE | ID: mdl-31672767
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Receptores CXCR4 / Mieloma Múltiplo Tipo de estudo: Clinical_trials Limite: Aged / Humans / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Receptores CXCR4 / Mieloma Múltiplo Tipo de estudo: Clinical_trials Limite: Aged / Humans / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article